Key result
Exenatide 10 µg twice daily for 3 months caused significant weight loss (P<0.001) and improved insulin sensitivity in non-diabetic, morbidly obese patients.
Why the study?
Does exenatide improve glucose fluxes, lipolysis, and ß-cell function in non-diabetic, morbidly obese patients?
Population
30 non-diabetic, morbidly obese subjects (n=15 per group)
Comparison
Exenatide 10 µg twice daily for 3 months vs Control for 3 months
Design
Cohort
Follow-up
3 months
Authors
Loading...
May support short-term GLP-1 use in non-diabetic obesity; leaves open confirmation of durability and outcomes in RCTs.
RCT (n=30)
Does exenatide improve glucose fluxes, lipolysis, and ß-cell function in non-diabetic, morbidly obese patients?
p-value: p=<.001
In morbidly obese non-diabetic patients, exenatide induces weight loss and improves insulin sensitivity by delaying oral glucose appearance, without altering ß-cell function.
Camastra et al. (2016) conducted an RCT in non-diabetic, morbidly obese (n=30). exenatide vs. control was evaluated on body weight, glucose disposal, insulin secretion, ß-cell function, lipolysis and hormone concentrations (p=<.001). Exenatide 10 µg twice daily for 3 months caused significant weight loss (P<0.001) and improved insulin sensitivity in non-diabetic, morbidly obese patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: